Identification of alemtuzumab-suitable multiple sclerosis patients in Slovakia and sequencing of post-alemtuzumab immunomodulatory treatment.
Kantorová E, Vítková M, Martiníková M, Cimprichová A, Fedicˇová M, Kovácˇová S, Mako M, Cisár J, Hancˇinová V, Szilasiová J, Koleda P, RoháIˇová J, Polóniová J, Karlík M, Slezáková D, Klímová E, Maciak M, Kurcˇa E, Hnilicová P.
Kantorová E, et al. Among authors: kurca e.
Ther Adv Neurol Disord. 2024 Oct 28;17:17562864241285556. doi: 10.1177/17562864241285556. eCollection 2024.
Ther Adv Neurol Disord. 2024.
PMID: 39494112
Free PMC article.